media – Page 591 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Emergency medical devices and equipment for every office

Accidents happen and emergencies arise in every office and in every industry and being prepared for situations such as these is vital.
- Source: Ddu
- 751
- January 26, 2018
Ddu College Emergency medical devices
York County sues 25 opioid manufacturers, distributors

With opioid-overdose deaths skyrocketing as 2017 comes to a close, York County is suing more than two dozen drug companies that "have intentionally misled the public about the dangers of opioids."
- Source: Yorkdispatch
- 604
- January 25, 2018
opioid polices
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

The commercial life for Novartis’ Arzerra outside the U.S. is coming to an end.
- Source: Fiercepharma
- 550
- January 25, 2018
Arzerra CLL Company Insight
Ddu College — China’s Import and Export Report of Peptic Ulcer Drugs

Peptic ulcers are open sores that develop on the inside lining of your stomach and the upper portion of your small intestine. The most common symptom of a peptic ulcer is stomach pain.
- Source: Ddu
- 42,748
- January 25, 2018
Ddu College Peptic ulcers
Boosting cancer therapy with cross-dressed immune cells

Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods. Immunotherapies are breakthrough treatments that stimulate the patient’s immune cells to attack the tumor through the recognition of aberrant molecules called tumor antigens. They can be very effective, but currently can only cure a minority of patients with solid tumors. Researchers and physicians are now looking into ways of increasing the precision and strength of the immune attack on the tumor. Dendritic cell vaccines One approach is the “dendritic cell vaccine”. Dendritic cells are specialized immune cells whose role is to capture antigens from foreign bodies and present them to the immune system’s killer T cells, which will then attack and destroy the invaders. For the vaccine, dendritic cells are taken out of the patient, “force-fed” with tumor antigens, and finally re-injected back into ...
- Source: medicalxpress
- 594
- January 25, 2018
artificial molecules cancer tumor immunotherapies Researches
Amgen Jumps as Migraine Drug Wows in Late-Stage Study

Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. On Monday, the company revealed Phase IIIb data that demonstrated the drug is also effective in reducing the number of episodic headaches in patients who have not responded to previous treatments.
- Source: biospace
- 625
- January 25, 2018
Aimovig Amgen Clinical Trials episodic headaches migraine
Chatbot campaign for flu shots bolsters patient response rate by 30%

Brett Swenson, MD, deployed a chatbot to improve engagement from EHRs to triage and found real success in reaching patients with information about flu shots.
- Source: Healthcare IT
- 582
- January 25, 2018
AI digital health Researches
Apple looking at easy access to your complete medical records

Chronic diseases and health conditions are often incurable and can adversely impact the longevity and quality of a person’s life if not managed actively. The wide prevalence of these conditions along with the fact that they are often preventable and frequently manageable with early detection and with the right health practices, calls for more focus on empowering patients in ongoing self-care.
- Source: Business Insider
- 717
- January 25, 2018
Apple Company Insight EHR health IT
China’s digital healthcare transformation – private hospital achieve HIMSS milestone

Explosive growth and groundbreaking digital transformations are underway in China’s enormous healthcare market, and now a Beijing hospital has become the first private healthcare organisation in the nation to achieve Stage 6 on the HIMSS EMRAM scale for its electronic medical record system.
- Source: Healthcare IT
- 538
- January 25, 2018
China health IT healthcare Market Views
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
- Source: Cnbc
- 993
- January 24, 2018
cancer CAR–T Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.